Scholarlink

Background <p>Entrectinib is a targeted therapy that has been approved for the treatment of ROS1-positive non-small cell lung cancer. However, this therapy is associated with known but rare cardiotoxic risks.</p> Case presentation <p>We report a case of ventricular tachyarrhythmias occurring on day 4 after entrectinib initiation in a 37-year-old Han Chinese man with ROS1-positive metastatic lung adenocarcinoma. The arrhythmias was refractory to pharmacologic and electrical therapy, resulting in hemodynamic collapse and the need for venoarterial extracorporeal membrane oxygenation. The diagnostic workup excluded other causes, and therapeutic plasma exchange led to rhythm stabilization and cardiac recovery. The patient was successfully weaned from extracorporeal membrane oxygenation by day 5.</p> Conclusions <p>This case highlights a potentially fatal early-phase cardiac complication of entrectinib and supports the use of early electrocardiographic monitoring and therapeutic plasma exchange as management and rescue strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Refractory ventricular tachyarrhythmias following entrectinib initiation in metastatic lung adenocarcinoma: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Lili Tang,
  • Weiwei Wan,
  • Hongtao Zhang,
  • Xiaoyue Li

摘要

Background

Entrectinib is a targeted therapy that has been approved for the treatment of ROS1-positive non-small cell lung cancer. However, this therapy is associated with known but rare cardiotoxic risks.

Case presentation

We report a case of ventricular tachyarrhythmias occurring on day 4 after entrectinib initiation in a 37-year-old Han Chinese man with ROS1-positive metastatic lung adenocarcinoma. The arrhythmias was refractory to pharmacologic and electrical therapy, resulting in hemodynamic collapse and the need for venoarterial extracorporeal membrane oxygenation. The diagnostic workup excluded other causes, and therapeutic plasma exchange led to rhythm stabilization and cardiac recovery. The patient was successfully weaned from extracorporeal membrane oxygenation by day 5.

Conclusions

This case highlights a potentially fatal early-phase cardiac complication of entrectinib and supports the use of early electrocardiographic monitoring and therapeutic plasma exchange as management and rescue strategies.